TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

Kosmider, Olivier; Gelsi‐Boyer, Véronique; Cheok, Meyling; Grabar, Sophie; Della-Valle, Véronique; Picard, Françoise; Viguié, F; Quesnel, Bruno; Beyne‐Rauzy, Odile; Solary, Éric; Vey, Norbert; Hunault, Mathilde; Fenaux, Pierre; Mansat‐De Mas, Véronique; Delabesse, Éric; Guardiola, Philippe; Lacombe, Catherine; Vainchenker, William; Preudhomme, Claude; Dreyfus, François; Bernard, Olivier; Birnbaum, Daniel; Fontenay, Michaëla; behalf of the Groupe Francophone des Myélodysplasies, on

doi:10.1182/blood-2009-04-215814

Public

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)

Published in Blood • Aug 7, 2009

Authors:

Olivier Kosmider

Véronique Gelsi‐Boyer

Meyling Cheok

Abstract

Oncogenic pathways underlying in the development of myelodysplastic syndromes (MDS) remain poorly characterized, but mutations of the ten-eleven translocation 2 (TET2) gene are frequently observed. In the present work, we evaluated the prognostic impact of TET2 mutations in MDS. Frameshift, nonsense...

Subject

Internal medicine

Hazard ratio

Myelodysplastic syndromes

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!